1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFMW
Sunshine Biopharma, Inc.US flagNASDAQ Capital Market
0.06
USD
-0.02
- -
276,320.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
24
35
36
35
Operating Margin (%)
- -
- -
-45,683.67
- -
- -
- -
-3,037.91
-807.83
-1,068.24
-199.6
-19.86
-16.67
-12.34
-12.9
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-2
-3
-1
-2
-2
-3
-12
-27
-5
-5
-6
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-96,774.47
- -
- -
- -
-7,860.85
-3,898.74
-5,444.41
-615.44
-18.7
-14.72
-16.46
-17.02
Working Capital
- -
- -
-1
- -
-1
- -
-1
- -
2
20
19
20
20
19
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
2
1
1
1
1
1
Total Equity
- -
- -
-1
- -
-1
- -
-1
-1
- -
22
21
24
23
22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28
27
25
Cash, Cash Equivalents & STI
9
9
7
Accounts Receivable, Net
4
3
4
Inventories
14
13
13
Total Current Liabilities
7
6
6
Payables & Accruals
6
6
6
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,126.98%
2,000.54%
-1.97%
Free Cash Flow
46.45%
89.56%
-57.48%
Net Income, GAAP
60.22%
81.79%
16.39%
Sales/Revenue/Turnover
- -
505.11%
4.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
9
8
10
35
2025
9
9
9
9
36
2026
8
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Steve N. Slilaty
Full Time Employees
52
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
6500 Trans-Canada Highway Pointe-Claire QC Canada H9R 0A5
IPO Date
Feb 15, 2022
CIK
0001402328
Website
sunshinebiopharma.com
Similar Companies
Sigma Advanced Systems Limited (MEGASOFT.BO)
Elixinol Wellness Limited (ELLXF)
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ)
SymBio Pharmaceuticals Limited (SYMQY)
Vinergy Capital Inc. (VIN.CN)
RIV Capital Inc. (RIV.CN)
Business
Sunshine Biopharma Inc (NASDAQ:SBFMW) operates as a pharmaceutical company focused on the research development and commercialization of life-saving medicines across oncology antivirals and generic pharmaceuticals primarily in Canada and the United States; founded in 2006 it maintains headquarters in Fort Lauderdale Florida with key operations through its wholly owned Canadian subsidiary Nora Pharma Inc. The company offers over 74 generic prescription drugs targeting osteoporosis cardiovascular antipsychotic antibacterial hypertension anti-inflammatory allergy antibiotic central nervous system diabetes urology antifungal antimalarial oncology gastroenterology and anticonvulsant indications including the recently launched generic Prucalopride (1mg and 2mg tablets) for chronic idiopathic constipation in adult women; it also provides nonprescription over-the-counter nutritional supplements such as Essential 9 amino acid capsules Essential Calcium-Vitamin D L-Citrulline and Taurine products. In proprietary development Sunshine advances K1.1 mRNA an mRNA-lipid nanoparticle for liver cancer Adva-27a a small-molecule chemotherapy for pancreatic cancer and SBFM-PL4 (PLpro protease inhibitor) for SARS coronavirus infections with plans for additional generic launches including NIOPEG a biosimilar of Neulasta and more than 12 new drugs in 2026. Recent developments include Nora Pharma's March 2025 acquisition of rights to two gastrointestinal drugs with Prucalopride already launched and the second planned within nine months targeting Canada's $200 million gastrointestinal market; the company anticipates further product launches throughout 2025 raised $2.46 million via stock offering in April 2025 and in October 2025 allocated $5 million for Bitcoin investment as a strategic treasury reserve asset executed through regulated custodians or ETFs.

Company News

APIChat

  • defenseworld.net

    Sunshine Biopharma (NASDAQ:SBFMW) Trading Up 27% – Here’s Why